• Customer Care : (+91) 98240 42701

Vildagliptin+ Metformin HCL

The combination of Vildagliptin and Metformin HCL is used for the effective management of type 2 diabetes mellitus. Vildagliptin is a DPP-4 inhibitor that increases insulin secretion and decreases glucagon secretion in response to meals, while Metformin is a biguanide that reduces hepatic glucose production and enhances insulin sensitivity. Together, they provide improved glycemic control.

  • Recommended Usage
Indications:
  • Management of type 2 diabetes mellitus in adults.
  • As an adjunct to diet and exercise to achieve better glycemic control.
  • Suitable for patients not adequately controlled on Metformin alone or as initial therapy in patients with inadequate control on lifestyle modifications.
Dosage & Administration:
  • Administered orally, typically twice daily with meals to reduce gastrointestinal side effects.
  • Common doses: Vildagliptin 50mg + Metformin 500mg/850mg/1000mg.
  • Maximum daily dose: Vildagliptin 100mg and Metformin 2000mg.
  • Adjust dosage based on glycemic response and renal function.
Precautions:
  • Contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to any component.
  • Use cautiously in patients with hepatic impairment or cardiovascular disease.
  • Monitor renal function and blood glucose levels regularly.
  • Discontinue immediately if signs of lactic acidosis or pancreatitis occur.
Key Benefits:
  • Dual Action: Combines two complementary mechanisms to enhance glycemic control.
  • Postprandial Glucose Control: Effectively reduces post-meal blood glucose levels.
  • Low Risk of Hypoglycemia: Minimal risk when used as directed.
  • Improved Adherence: Simplifies treatment by combining two medications in one.
whatsapp